[Zurück]
 
Bitte auswählen
Jahr
Details
Sprache
Sortierung
Ausgabe
neu: RTF !
 Forschungsbericht für das Jahr 2018

Department für Radiologische Diagnostik und Therapie

Klinik für Strahlenheilkunde

Robert Koch Str. 3
79106 Freiburg
Tel: 0049-761-270-9461 Fax: 0049-761-270-9472
Email anca.grosu@uniklinik-freiburg.de


Wissenschaftliche Mitarbeiterinnen und Mitarbeiter

  • Prof. Dr. med. Anca-Ligia Grosu, Ärztliche Direktorin
  • Nils PD Dr. Dr. med. Nicolay, Leitender Oberarzt
  • PD Dr. Dr. med. Nils Nicolay, Leitender Oberarzt
  • Dr. med. Marianne Schmucker, Geschäftsführende Oberärztin
  • Prof. Dr. Dimos Baltas, Leiter der Abt. Medizinische Physik
  • Dr. med. Karl Henne, OA
  • Dr. medic/IM Temeschburg Carmen Martini, OÄ
  • Prof. Dr. med. Ursula Nestle
  • Dr. med. Henning Schäfer, OA
  • Dr. med. Jutta Scholber, OÄ
  • Dr. med. Sonja Adebahr
  • Dr. med. Angelika Bilger
  • Hatice Bunea
  • Dr. med./Univ. Andrei Bunea
  • Jamina Tara Fennell
  • Dr. med. Eleni Gkika
  • Dr. med. Emily Kim
  • Dr. med. Simon Kirste
  • Dr. med. Nicole Landenberger
  • Moritz Luttke, Assistenzarzt
  • Dr. med. Ilinca Popp
  • PD Dr. med. Hans Christian Rischke
  • Nasr Salman
  • Dr. med. Tanja Schimek-Jasch
  • Daniel Schnell
  • Lina Steffan, Assistenzärztin
  • Dr. med. Andreas Thomsen
  • Dr. /VAK Moskau Natascha Volegova-Neher
  • Dr. med. Nicole Wiedenmann
  • Dr. med. Constantinos Zamboglou
  • Amelia Cascajo Castresana
  • Dr. Mark Gainey
  • Dr. rer. nat. Michael Kollefrath
  • Dr. Kodor Koubar
  • Dipl. Phys. Sophie Küchler
  • Dr. Jördis Lübke
  • Dr. Ing. Thomas Rothe
  • Dr. rer. nat. Rolf Wiehle
  • Dr. med. Felix Heinemann, Leiter Klinische und Administrative Informatik
  • Prof. Dr. med. Gabriele Niedermann, Leiterin Sektion Strahlenbiologie
  • Dr. rer. nat. Elke Firat
Einträge in der Rubrik "Who is Who"

Wissenschaftliche Projekte und Forschungsvorhaben


  • Assoziation zw. dem Schweregrad einer Mukositis, der Verängerung verschiedener Speichelparamteter und der zellulären Wundheilungspotenz währen sowie nach einer Strahlentherapie im Kopf-Hals-Bereich
  • CAO/ARO/AIO-12
  • CONKO-07
  • EMR100036-002 Eine offene Phase Ia / Ib-Studie mit dem DNA-PK-Inhibitor MSC2490484A in Kombination mit Strahlentherapie bei Patienten mit fortgeschrittenen soliden Tumoren
  • ESOPEC
  • F-MISO-PET
  • GLIAA - Aminosäure-PET versus MRT gesteuerte Re-Bestrahlung bei Patienten mit rezidiviertem Glioblastoma multiforme - eine randomisierte Phase II klinische Studie -
  • Hipporad MC-Studie
  • L-AP-IS
  • LARIS
  • LungArt
  • LungTech EORTC 22113-08113
  • PEACE 1
  • PEACE 2
  • PEGASUS
  • PET-Plan-Studie
  • PORTAF
  • Tumorspezifische Immunität und Inflammation beim Malignen Melanom
  • Verbundprojekt ZiSStrans: Zielstrukturen der individuellen Strahlenempfindlichkeit, Teilprojekt F

Wissenschaftliche Publikationen

Originalarbeiten in wissenschaftlichen Fachzeitschriften:
  • Akbaba S, Foerster R, Nicolay NH, Arians N, Bostel T, Debus J, Hauswald H: Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma. Radiat Oncol, 2018; 13 (1) (online). : http://dx.doi.org/10.1186/s13014-018-1088-9
  • Akbaba S, Oelmann-Avendano JT, Bostel T, Rief H, Nicolay NH, Debus J, Lindel K, Foerster R: Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life. Radiol Oncol, 2018; 52 (3): 320-328. : http://dx.doi.org/10.2478/raon-2018-0029
  • Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, Buettner N, Kirste S, Nestle U, Grosu AL, Thimme R, Brunner TB: Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis. Bmc Cancer, 2018; 18 (1) (online). : http://dx.doi.org/10.1186/s12885-018-4696-8
  • Bilger A, Bretzinger E, Fennell J, Nieder C, Lorenz H, Oehlke O, Grosu AL, Specht HM, Combs SE: Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection. Cancer Med-us, 2018; 7 (6): 2350-2359. : http://dx.doi.org/10.1002/cam4.1486
  • Bostel T, Nicolay NH, Welzel T, Bruckner T, Mattke M, Akbaba S, Sprave T, Debus J, Uhl M: Sacral insufficiency fractures after high-dose carbon-ion based radiotherapy of sacral chordomas. Radiat Oncol, 2018; 13 (1) (online): 154-154. : http://dx.doi.org/10.1186/s13014-018-1095-x
  • Bostel T, Pfaffenberger A, Delorme S, Dreher C, Echner G, Haering P, Lang C, Splinter M, Laun F, Muller M, Jakel O, Debus J, Huber PE, Sterzing F, Nicolay NH: Prospective feasibility analysis of a novel off-line approach for MR-guided radiotherapy. Strahlenther Onkol, 2018; 194 (5): 425-434. : http://dx.doi.org/10.1007/s00066-017-1258-y
  • Chatzikonstantinou G, Zamboglou N, Archavlis E, Strouthos I, Zoga E, Milickovic N, Hilaris B, Baltas D, Rodel C, Tselis N: CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience. Strahlenther Onkol, 2018. : http://dx.doi.org/10.1007/s00066-018-1358-3 (in Druck)
  • Combs SE, Bilger A, Diehl C, Bretzinger E, Lorenz H, Oehlke O, Specht HM, Kirstein A, Grosu AL: Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases. Cancer Med-us, 2018; 7 (6): 2319-2327. : http://dx.doi.org/10.1002/cam4.1477
  • Combs SE, Farzin M, Boehmer J, Oehlke O, Molls M, Debus J, Grosu AL: Clinical outcome after high-precision radiotherapy for skull base meningiomas: Pooled data from three large German centers for radiation oncology. Radiother Oncol, 2018; 127 (2): 274-279. : http://dx.doi.org/10.1016/j.radonc.2018.03.006
  • El Shafie RA, Bougatf N, Sprave T, Weber D, Oetzel D, Machmer T, Huber PE, Debus J, Nicolay NH: Oncologic Therapy Support Via Means of a Dedicated Mobile App (OPTIMISE-1): Protocol for a Prospective Pilot Trial. Jmir Mhealth Uhealth, 2018; 7 (3) (online). : http://dx.doi.org/10.2196/resprot.8915
  • El Shafie RA, Weber D, Bougatf N, Sprave T, Oetzel D, Huber PE, Debus J, Nicolay NH: Supportive Care in Radiotherapy Based on a Mobile App: Prospective Multicenter Survey. Jmir Mhealth Uhealth, 2018; 6 (8) (online): e10916-e10916. : http://dx.doi.org/10.2196/10916
  • Foerster R, Hees K, Bruckner T, Bostel T, Schlampp I, Sprave T, Nicolay NH, Debus J, Rief H: Survival and Stability of Patients with Urothelial Cancer and Spinal Bone Metastases after Palliative Radiotherapy. Radiol Oncol, 2018; 52 (2): 189-194. : http://dx.doi.org/10.1515/raon-2017-0038
  • Gainey M, Carles M, Mix M, Meyer PT, Bock M, Grosu AL, Baltas D: Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects. Future Oncol, 2018; 14 (8): 737-749. : http://dx.doi.org/10.2217/fon-2017-0464
  • Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu AL, Brunner TB: The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol, 2018; 194 (5): 403-413. : http://dx.doi.org/10.1007/s00066-017-1256-0
  • Gkika E, Oehlke O, Bunea H, Wiedenmann N, Adebahr S, Nestle U, Zamboglou C, Kirste S, Fennell J, Brunner T, Gainey M, Baltas D, Langer M, Urbach H, Bock M, Meyer PT, Grosu AL: Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects. Future Oncol, 2018; 14 (8): 751-769. : http://dx.doi.org/10.2217/fon-2017-0465
  • Gkika E, Vach W, Adebahr S, Schimek-Jasch T, Brenner A, Brunner TB, Kaier K, Prasse A, Muller-Quernheim J, Grosu AL, Zissel G, Nestle U: Correction: Is serum level of CC chemokine ligand 18 a biomarker for the prediction of radiation induced lung toxicity (RILT)? Plos One, 2018; 13 (1): e0192058-e0192058. : http://dx.doi.org/10.1371/journal.pone.0192058
  • Heiland DH, Haaker G, Watzlawick R, Delev D, Masalha W, Franco P, Machein M, Staszewski O, Oelhke O, Nicolay NH, Schnell O: Correction to: One decade of glioblastoma multiforme surgery in 342 elderly patients: what have we learned? J Neuro-oncol, 2018. : http://dx.doi.org/10.1007/s11060-018-2994-2 (in Druck)
  • Hess J, Unger K, Maihoefer C, Schuttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rodel C, Stuschke M, Zips D, Zitzelsberger HF, Ganswindt U, Henke M, Belka C: A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV-infection. Clin Cancer Res, 2018. : http://dx.doi.org/10.1158/1078-0432.CCR-18-0776 (in Druck)
  • Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X: Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells. Hum Gene Ther, 2018. : http://dx.doi.org/10.1089/hum.2017.234 (in Druck)
  • Karagiannis E, Leczynski A, Tselis N, Psanis E, Steckenreiter O, Milickovic N, Bon D, Strouthos I, Ferentinos K, Hass P, Gademann G, Baltas D, Zamboglou N: Inverse planning and inverse implanting for breast interstitial brachytherapy. Introducing a new anatomy specific breast interstitial template (ASBIT). Radiother Oncol, 2018; 128 (3): 421-427. : http://dx.doi.org/10.1016/j.radonc.2018.06.003
  • Kirste S, Kayser G, Zipfel A, Grosu AL, Brunner T: Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection. Radiat Oncol, 2018; 13 (1): 28-28. : http://dx.doi.org/10.1186/s13014-018-0974-5
  • Krauze AV, Attia A, Braunstein S, Chan M, Combs SE, Fietkau R, Fiveash J, Flickinger J, Grosu A, Howard S, Nieder C, Niyazi M, Rowe L, Smart DD, Tsien C, Camphausen K: Correction to expert consensus on re-irradiation for recurrent glioma. Radiat Oncol, 2018; 13 (1): 8-8. : http://dx.doi.org/10.1186/s13014-018-0955-8
  • Lazzeroni M, Bunea H, Grosu AL, Baltas D, Toma-Dasu I, Dasu A: Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging. Adv Exp Med Biol, 2018; 1072: 195-200. : http://dx.doi.org/10.1007/978-3-319-91287-5_31
  • Luo R, Wu VWC, He B, Gao X, Xu Z, Wang D, Yang Z, Li M, Lin Z: Development of a normal tissue complication probability (NTCP) model for radiation-induced hypothyroidism in nasopharyngeal carcinoma patients. Bmc Cancer, 2018; 18 (1): 575-575. : http://dx.doi.org/10.1186/s12885-018-4348-z
  • Luttke M, Nicolay NH: [Neoadjuvant chemoradiotherapy does not negatively impact the postoperative quality of life of esophageal cancer patients]. Strahlenther Onkol, 2018; 194 (8): 794-796. : http://dx.doi.org/10.1007/s00066-018-1323-1
  • Munz F, Lopez Perez R, Trinh T, Sisombath S, Weber KJ, Wuchter P, Debus J, Saffrich R, Huber PE, Nicolay NH: Human mesenchymal stem cells lose their functional properties after paclitaxel treatment. Sci Rep-uk, 2018; 8 (1) (online): 312-312. : http://dx.doi.org/10.1038/s41598-017-18862-1
  • Nicolay NH: [A close web-based patient follow-up improves overall survival in lung cancer patients]. Strahlenther Onkol, 2018; 194 (6): 604-606. : http://dx.doi.org/10.1007/s00066-018-1297-z
  • Nieder C, Hintz M, Bilger A, Oehlke O, Grosu AL: Validation of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). J Clin Med Res, 2018; 10 (3): 178-181. : http://dx.doi.org/10.14740/jocmr3248w
  • Nieder C, Mehta MP, Geinitz H, Grosu AL: Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms. Crit Rev Oncol Hemat, 2018; 126: 13-18. : http://dx.doi.org/10.1016/j.critrevonc.2018.03.018
  • Niyazi M, Adeberg S, Kaul D, Boulesteix AL, Bougatf N, Fleischmann DF, Grun A, Kramer A, Rodel C, Eckert F, Paulsen F, Kessel KA, Combs SE, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J: Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. Radiother Oncol, 2018; 127 (1): 121-127. : http://dx.doi.org/10.1016/j.radonc.2018.01.011
  • Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholoma M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kroger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R: Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med, 2018; 10 (429): 1-12. : http://dx.doi.org/10.1126/scitranslmed.aam7729
  • Ruhle A, Huber PE, Saffrich R, Lopez Perez R, Nicolay NH: The current understanding of mesenchymal stem cells as potential attenuators of chemotherapy-induced toxicity. Int J Cancer, 2018. : http://dx.doi.org/10.1002/ijc.31619 (in Druck)
  • Ruhle A, Xia O, Perez RL, Trinh T, Richter W, Sarnowska A, Wuchter P, Debus J, Saffrich R, Huber PE, Nicolay NH: The Radiation Resistance of Human Multipotent Mesenchymal Stromal Cells Is Independent of Their Tissue of Origin. Int J Radiat Oncol, 2018; 100 (5): 1259-1269. : http://dx.doi.org/10.1016/j.ijrobp.2018.01.015
  • Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C: Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. J Nucl Med, 2018. : http://dx.doi.org/10.2967/jnumed.118.212563 (in Druck)
  • Schmidt S, Linge A, Zwanenburg A, Leger S, Lohaus F, Krenn C, Appold S, Gudziol V, Nowak A, von Neubeck C, Tinhofer I, Budach V, Sak A, Stuschke M, Balermpas P, Rodel C, Bunea H, Grosu AL, Abdollahi A, Debus J, Ganswindt U, Belka C, Pigorsch S, Combs SE, Monnich D, Zips D, Baretton GB, Buchholz F, Baumann M, Krause M, Lock S: Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. Clin Cancer Res, 2018; 24 (6): 1364-1374. : http://dx.doi.org/10.1158/1078-0432.CCR-17-2345
  • Sprave T, Hees K, Bruckner T, Foerster R, Bostel T, Schlampp I, El Shafie R, Nicolay NH, Debus J, Rief H: The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases. Radiat Oncol, 2018; 13 (1) (online). : http://dx.doi.org/10.1186/s13014-018-1082-2
  • Sprave T, Verma V, Forster R, Schlampp I, Bruckner T, Bostel T, El Shafie RA, Nicolay NH, Debus J, Rief H: Quality of Life Following Stereotactic Body Radiotherapy Versus Three-Dimensional Conformal Radiotherapy for Vertebral Metastases: Secondary Analysis of an Exploratory Phase II Randomized Trial. Anticancer Res, 2018; 38 (8): 4961-4968. : http://dx.doi.org/10.21873/anticanres.12814
  • Sprave T, Verma V, Forster R, Schlampp I, Bruckner T, Bostel T, Welte SE, Tonndorf-Martini E, El Shafie R, Nicolay NH, Debus J, Rief H: Radiation-induced acute toxicities after image-guided intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for patients with spinal metastases (IRON-1 trial) : First results of a randomized controlled trial. Strahlenther Onkol, 2018; 194 (10): 911-920. : http://dx.doi.org/10.1007/s00066-018-1333-z
  • Sprave T, Verma V, Forster R, Schlampp I, Bruckner T, Bostel T, Welte SE, Tonndorf-Martini E, Nicolay NH, Debus J, Rief H: Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol, 2018; 128 (2): 274-282. : http://dx.doi.org/10.1016/j.radonc.2018.04.030
  • Sprave T, Verma V, Forster R, Schlampp I, Hees K, Bruckner T, Bostel T, El Shafie RA, Welzel T, Nicolay NH, Debus J, Rief H: Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial. Bmc Cancer, 2018; 18 (1): 859-859. : http://dx.doi.org/10.1186/s12885-018-4777-8
  • Sprave T, Verma V, Forster R, Schlampp I, Hees K, Bruckner T, Bostel T, El Shafie R, Nicolay NH, Debus J, Rief H: Quality of Life and Radiation-induced Late Toxicity Following Intensity-modulated Versus Three-dimensional Conformal Radiotherapy for Patients with Spinal Bone Metastases: Results of a Randomized Trial. Anticancer Res, 2018; 38 (8): 4953-4960. : http://dx.doi.org/10.21873/anticanres.12813
  • Sprave T, Welte SE, Bruckner T, Forster R, Bostel T, Schlampp I, Nicolay NH, Debus J, Rief H: Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial. Trials, 2018; 19 (1): 59-59. : http://dx.doi.org/10.1186/s13063-018-2452-7
  • Strouthos I, Chatzikonstantinou G, Zamboglou N, Milickovic N, Papaioannou S, Bon D, Zamboglou C, Rodel C, Baltas D, Tselis N: Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiother Oncol, 2018; 128 (2): 301-307. : http://dx.doi.org/10.1016/j.radonc.2018.04.031
  • Tanner JM, Nicolay NH: [When a name becomes a unit: Rolf Maximilian Sievert]. Radiologe, 2018; 58 (2): 153-158. : http://dx.doi.org/10.1007/s00117-017-0321-0
  • Thomsen AR, Aldrian C, Bronsert P, Thomann Y, Nanko N, Melin N, Rucker G, Follo M, Grosu AL, Niedermann G, Layer PG, Heselich A, Lund PG: A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement. Lab Chip, 2018; 18 (1): 179-189. : http://dx.doi.org/10.1039/c7lc00832e
  • Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Buchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL: Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET. Radiat Oncol, 2018; 13 (1) (online). : http://dx.doi.org/10.1186/s13014-018-1134-7
  • Zamboglou C, Grosu AL: [Combination of percutaneous radiotherapy, brachytherapy, and androgen deprivation equivalent alternatives to radical prostatectomy for prostate cancer]. Strahlenther Onkol, 2018; 194 (4): 360-362. : http://dx.doi.org/10.1007/s00066-018-1273-7
  • Zamboglou C, Klein CM, Thomann B, Fassbender TF, Rischke HC, Kirste S, Henne K, Volegova-Neher N, Bock M, Langer M, Meyer PT, Baltas D, Grosu AL: The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiat Oncol, 2018; 13 (1): 65-65. : http://dx.doi.org/10.1186/s13014-018-1014-1
  • Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL: Focal dose escalation for prostate cancer using (68)Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference. Radiat Oncol, 2018; 13 (1): 81-81. : http://dx.doi.org/10.1186/s13014-018-1036-8
  • Zhang X, Niedermann G: Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response. Int J Radiat Oncol, 2018; 101 (1): 63-73. : http://dx.doi.org/10.1016/j.ijrobp.2018.01.094
  • Zschaeck S, Lohaus F, Beck M, Habl G, Kroeze S, Zamboglou C, Koerber SA, Debus J, Holscher T, Wust P, Ganswindt U, Baur ADJ, Zophel K, Cihoric N, Guckenberger M, Combs SE, Grosu AL, Ghadjar P, Belka C: PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. Radiat Oncol, 2018; 13 (1): 90-90. : http://dx.doi.org/10.1186/s13014-018-1047-5

Besondere wissenschaftliche Aktivitäten

Vorsitze und Sprechertätigkeiten:
  • Prof. Dr. med. Anca-L.Grosu, Heinemann F, Röhner F, Schmucker M: Elektronische Krankenakte in der Strahlenheilkunde, DEGRO Ausschuss, seit 09.07.2009.
  • Prof. Dr. med. Anca-L. Grosu: Vorstandsvorsitzende der Hanns-Langendorf-Stiftung, seit 2010.
  • Prof. Dr. med. Anca-Ligia Grosu: Vorstandsmitglied der Deutschen Neuroonkologischen Arbeitsgruppe (NOA), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied des unabhängigen Expertengremiums der Deutschen Gesellschaft für Radioonkologie (DEGRO), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Arbeitsgemeinschaft Radiologische Onkologie (ARO), seit 2011.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied des Geschäftsführenden Vorstands des Comprehensive Cancer Centers, Universitätsklinikum Freiburg (CCCF), seit 2012.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied im Beirat des Comprehensive Cancer Centers Graz (CCC Graz), Österreich, seit 2014.
  • Prof. Dr. med. Anca-Ligia Grosu: Stellvertretende Vorsitzende des Deutschen Konsortiums für Translationale Krebsmedizin, Universitätsklinikum Freiburg (DKTK Partnerstandort Freiburg) , seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied im Senat der Albert-Ludwigs-Universität Freiburg , seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktionsleitung der Fachzeitschrift "Radiotherapy and Oncology" (The Green Journal), seit 2015.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktion der Fachzeitschrift "Strahlentherapie und Onkologie", seit 2016.
  • Prof. Dr. med. Anca-Ligia Grosu: Mitglied der Redaktionsleitung der Fachzeitschrift "Physics and Imaging in Radiation Oncology", seit 01.08.2016.
  • Prof. Dr. med. Ursula Nestle: Vorsitzende des Ausschusses "Strahlenschutz in der Medizin" Strahlenschutzkommission , seit 2015.

Abschlussarbeiten